SiRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA

Nucleic Acid Therapeutics

Volumn 25, Issue 2, 2015, Pages 53-64

  Zuckerman, Jonathan E ^a   Gale, Aaron ^a   Wu, Peiwen ^b   Ma, Rong ^b   Davis, Mark E ^a  

^a California Institute of Technology   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLODEXTRIN; ENHANCED GREEN FLUORESCENT PROTEIN; LIGAND; MANNOSE; NANOPARTICLE; SMALL INTERFERING RNA; TRANSFERRIN; CATION; DRUG CARRIER;

ANIMAL CELL; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; GENE EXPRESSION; GENE SILENCING; GLOMERULUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; KIDNEY TUBULE CELL; LIVER SINUSOID; MESANGIUM; MESANGIUM CELL; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; REPORTER GENE; SPLEEN; SPLENIC RED PULP; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; FEMALE; METABOLISM;

ANIMALS; CATIONS; CYCLODEXTRINS; DRUG CARRIERS; FEMALE; GLOMERULAR MESANGIUM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NANOPARTICLES; RNA, SMALL INTERFERING;

EID: 84961301013     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2014.0505     Document Type: Article

References (36)

1. United States Renal Data System. (2014). 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
2. Davis ME, ZG Chen and DM Shin. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771-782.
3. Castanotto D and JJ Rossi. (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature 457:426-433.
4. Zuckerman JE and ME Davis. (2013). Targeting therapeutics to the glomerulus with nanoparticles. Adv Chronic Kidney Dis 20:500-507.
5. Choi CHJ, JE Zuckerman, P Webster and ME Davis. (2011). Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci (USA) 108:6656-6661.
6. Liao J, K Hayashi, S Horikoshi, H Ushijima, J Kimura and Y Tomino. (2001). Effect of steroid-liposome on im-munohistopathology of IgA nephropathy in ddY mice. Nephron 89:194-200.
7. Morimoto K, M Kondo, K Kawahara, H Ushijima, Y To-mino, M Miyajima and J Kimura. (2007). Advances in targeting drug delivery to glomerular mesangial cells by long circulating cationic liposomes for the treatment of glomerulonephritis. Pharm Res 24: 946-54.
8. Asgeirsdóttir SA, JA Kamps, HI Bakker, PJ Zwiers, P Heeringa, K Van Der Weide, H Van Goor, AH Petersen, H Morselt, et al. (2007). Site-specific inhibition of glomerulo-nephritis progression by targeted delivery of dexamethasone to glomerular endothelium. Mol Pharmacol 72:121-131.
9. Suana AJ, G Tuffin, BM Frey, L Knudsen, C Mu, S Ro and H Marti. (2011). Single application of low-dose myco-phenolate mofetil-OX7-Immunoliposomes ameliorates experimental mesangial proliferative glomerulonephritis. Pharmacology 337:411-422.
10. Shimizu H, Y Hori, S Kaname, K Yamada, N Nishiyama, S Matsumoto, K Miyata, M Oba, A Yamada, K Kataoka and T Fujita T. (2010). siRNA-based therapy ameliorates glo-merulonephritis. J Am Soc Nephrol 21:622-633.
11. Hauser PV, JW Pippin, C Kaiser, RD Krofft, PT Brink-koetter, KL Hudkins, D Kerjaschki, J Reiser, CE Alpers and SJ Shankland. (2010). Novel siRNA delivery system to target podocytes in vivo. PloS One 5:e9463.
12. Zuckerman JE, CH Choi, H Han and ME Davis. Polyca-tion-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane.(2012). Proc Natl Acad Sci (USA) 109:3137-3142.
13. Davis ME, JE Zuckerman, CH Choi, D Seligson, A Tolcher, CA Alabi, Y Yen, JD Heidel and A Ribas. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067-1070.
14. Bartlett DW and ME Davis. (2007). Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem 18:456-468.
15. Novina CD, MF Murray, DM Dykxhoorn, PJ Beresford, J Riess, S-K Lee, RG Collman, J Lieberman, P Shankar and PA Sharp. (2002). siRNA-directed inhibition of HIV-1 infection. Nat Med 8:681-686.
16. Takemoto M, N Asker, H Gerhardt, A Lundkvist, BR Johansson, Y Saito and C Betsholtz. (2002). A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 161:799-805.
17. Bartlett DW, H Su, IJ Hildebrandt, WA Weber and ME Davis. (2007). Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci (USA) 104:15549-1554.
18. Kamaly N, Z Xiao, PM Valencia, AF Radovic-Moreno and OC Farokhzad. (2012). Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 41:2971-3010.
19. Linehan S, L Martínez-Pomares, PD Stahl and S Gordon. (1999). Mannose receptor and its putative ligands in normal murine lymphoid and nonlymphoid organs: in situ expression of mannose receptor by selected macrophages, endo-thelial cells, perivascular microglia, and mesangial cells, but not dendritic cells. J Exp Med 189:1961-1972.
20. Zhang XS, W Brondyk, JT Lydon, BL Thurberg and P Piepenhagen. (2011). Biotherapeutic target or sink: analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases. J Inherit Metab Dis 34:795-809.
21. Bellocq NC, SH Pun, GS Jensen and ME Davis. (2003). Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 14:1122-1132.
22. Zhang D, E Meyron-Holtz and T Rouault. (2007). Renal iron metabolism: transferrin iron delivery and the role of iron regulatory proteins. J Am Soc Nephrol 18:401-406.
23. Popielarski SR, S Hu-Lieskovan, SW French, TJ Triche and ME Davis. (2005). A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results. Bioconjug Chem 16:1071-1080.
24. Sraer JD, C Adida, MN Peraldi, E Rondeau and A Kanfer. (1993). Species-specific properties of the glomerular me-sangium. J Am Soc Nephrol 3:1342-1350.
25. Kawakami S, A Sato, M Nishikawa, F Yamashita and M Hashida. (2000). Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic lipo-somes. Gene Ther 7:292-299.
26. Wada K, H Arima, T Tsutsumi, Y Chihara, K Hattori, F Hirayama and K Uekama. (2005). Improvement of gene delivery mediated by mannosylated dendrimer/alpha-cyclodextrin conjugates. J Control Release 104:397-413.
27. Haddad E. (2003). Enhanced expression of the CD71 me-sangial IgA1 receptor in Berger disease and Henoch-Schonlein nephritis: association between CD71 expression and IgA deposits. J Am Soc Nephrol 14:327-337.
28. Moura IC, MN Centelles, M Arcos-Fajardo, DM Mal-heiros, JF Collawn, MD Cooper and RC Monteiro. (2001). Identification of the transferrin receptor as a novel immuno-globulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 194:417-425.
29. Berthelot L, C Papista, TT Maciel, M Biarnes-Pelicot, E Tissandie, PH Wang, H Tamouza, A Jamin, J Bex-Coudrat, et al. (2012). Transglutaminase is essential for IgA ne-phropathy development acting through IgA receptors. The J Exp Med 209:793-806.
30. Yuan H, L Lanting, Z-G Xu, S-L Li, P Swiderski, S Putta, M Jonnalagadda, M Kato and R Natarajan. (2008). Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes. Am J Physiol Renal Physiol 295:F605-F617.
31. Stokman G, Y Qin, Z Rácz, P Hamar and LS Price. (2010). Application of siRNA in targeting protein expression in kidney disease. Adv Drug Deliv Rev 62:1378-1389.
32. Ito K, J Chen, JJ Khodadadian, SV Seshan, C Eaton, X Zhao, ED Vaughan, M Lipkowitz, DP Poppas and D Fel-sen. (2004). Liposome-mediated transfer of nitric oxide synthase gene improves renal function in ureteral obstruction in rats. Kidney Int 66:1365-1375.
33. Tuffin G, E Waelti, J Huwyler, C Hammer and H-P Marti. (2005). Immunoliposome targeting to mesangial cells a promising strategy for specific drug delivery to the kidney. J Am Soc Nephrol 16:3295-3305.
34. Scindia Y, U Deshmukh, P-R Thimmalapura and H Ba-gavant. (2008). Anti-alpha8 integrin immunoliposomes in glomeruli of lupus-susceptible mice: a novel system for delivery of therapeutic agents to the renal glomerulus in systemic lupus erythematosus. Arthritis Rheum 58: 3884-3891.
35. Asgeirsdóttir SA, PJ Zwiers, HW Morselt, HE Moorlag, HI Bakker, P Heeringa, JW Kok, CG Kallenberg, G Molema and JM Kamps. (2008). Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexa-methasone-loaded AbEsel liposomes. Am J Physiol Renal Physiol 294:F554-F561.
36. Wu P, Y Wang, ME Davis, JE Zuckerma, S Chaudhari, M Begg M and R Ma. (2015). Store-operated Ca2+ channel in mesangial cells inhibits matrix protein expression. J Am Soc Nephrol. Submitted.